These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19114693)

  • 1. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.
    Follo MY; Finelli C; Clissa C; Mongiorgi S; Bosi C; Martinelli G; Baccarani M; Manzoli L; Martelli AM; Cocco L
    J Clin Oncol; 2009 Feb; 27(5):782-90. PubMed ID: 19114693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome.
    Follo MY; Bosi C; Finelli C; Fiume R; Faenza I; Ramazzotti G; Gaboardi GC; Manzoli L; Cocco L
    Int J Mol Med; 2006 Aug; 18(2):267-71. PubMed ID: 16820933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia.
    Lo Vasco VR; Calabrese G; Manzoli L; Palka G; Spadano A; Morizio E; Guanciali-Franchi P; Fantasia D; Cocco L
    Leukemia; 2004 Jun; 18(6):1122-6. PubMed ID: 15085153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoinositide phospholipase Cbeta1 (PI-PLCbeta1) gene in myelodysplastic syndromes and cytogenetically normal acute myeloid leukemia: not a deletion, but increased PI-PLCbeta1 expression is an independent prognostic factor.
    Damm F; Lange K; Heuser M; Oberacker T; Morgan M; Wagner K; Krauter J; Schlegelberger B; Ganser A; Göhring G
    J Clin Oncol; 2010 Aug; 28(22):e384-7; author reply e388-9. PubMed ID: 20516454
    [No Abstract]   [Full Text] [Related]  

  • 5. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
    Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
    Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear phospholipase C beta1, regulation of the cell cycle and progression of acute myeloid leukemia.
    Cocco L; Manzoli L; Palka G; Martelli AM
    Adv Enzyme Regul; 2005; 45():126-35. PubMed ID: 16024064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.
    Follo MY; Finelli C; Mongiorgi S; Clissa C; Bosi C; Testoni N; Chiarini F; Ramazzotti G; Baccarani M; Martelli AM; Manzoli L; Martinelli G; Cocco L
    Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16811-6. PubMed ID: 19805378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
    Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
    Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment.
    Follo MY; Russo D; Finelli C; Mongiorgi S; Clissa C; Filì C; Colombi C; Gobbi M; Manzoli L; Piazzi M; Martelli AM; Cocco L
    Leukemia; 2012 May; 26(5):943-50. PubMed ID: 22033492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
    Follo MY; Finelli C; Mongiorgi S; Clissa C; Chiarini F; Ramazzotti G; Paolini S; Martinelli G; Martelli AM; Cocco L
    Leukemia; 2011 Feb; 25(2):271-80. PubMed ID: 21109771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Submicroscopic deletions in 5q- associated malignancies.
    Crescenzi B; La Starza R; Romoli S; Beacci D; Matteucci C; Barba G; Aventin A; Marynen P; Ciolli S; Nozzoli C; Martelli MF; Mecucci C
    Haematologica; 2004 Mar; 89(3):281-5. PubMed ID: 15020265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
    Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
    J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI-PLCβ1 gene copy number alterations in breast cancer.
    Molinari C; Medri L; Follo MY; Piazzi M; Mariani GA; Calistri D; Cocco L
    Oncol Rep; 2012 Feb; 27(2):403-8. PubMed ID: 22076473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiology and pathology of nuclear phospholipase C β1.
    Cocco L; Follo MY; Faenza I; Fiume R; Ramazzotti G; Weber G; Martelli AM; Manzoli FA
    Adv Enzyme Regul; 2011; 51(1):2-12. PubMed ID: 21035488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphoinositide-specific phospholipase C beta1 signal transduction in the nucleus.
    Fiume R; Teti G; Faenza I; Cocco L
    Methods Mol Biol; 2010; 645():143-64. PubMed ID: 20645187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear Inositide Signaling Via Phospholipase C.
    Ratti S; Mongiorgi S; Ramazzotti G; Follo MY; Mariani GA; Suh PG; McCubrey JA; Cocco L; Manzoli L
    J Cell Biochem; 2017 Aug; 118(8):1969-1978. PubMed ID: 28106288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes.
    Kurata M; Hasegawa M; Nakagawa Y; Abe S; Yamamoto K; Suzuki K; Kitagawa M
    Exp Mol Pathol; 2006 Dec; 81(3):249-54. PubMed ID: 16566920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.